Ulinastatin in the treatment of severe acute pancreatitis: A single-center randomized controlled trial

Table 1 Comparison of baseline data

	UTI group (n = 91)	Placebo group (n = 90)	P value
Age (year, mean ± SD)	52.7 ± 3.8	53.5 ± 4.1	0.175
Gender, n (%)			0.705
Male	67 (73.63)	64 (71.11)
Female	24 (26.37)	26 (28.88)
BMI (kg/cm2, mean ± SD)	22.6 ± 2.1	23.1 ± 2.5	0.147
Cause of disease, n (%)			0.582
Biliary	61 (67.03)	57 (63.33)
Hyperlipidemic	18 (19.78)	19 (21.11)
Alcoholic	12 (13.09)	14 (15.56)
Smoking history, n (%)			0.483
Yes	53 (58.24)	57 (63.33)
No	38 (41.76)	33 (36.67)
Drinking history, n (%)			0.371
Yes	58 (58.24)	63 (70.00)
No	33 (41.76)	27 (30.00)
Living environment, n (%)			0.604
Town	59 (64.84)	55 (61.11)
Countryside	32 (35.16)	35 (38.89)
Past medical history, n (%)
Hypertension	31 (34.07)	29 (32.22)	0.792
Hyperlipidemia	35 (38.46)	37 (41.11)	0.716
Diabetes	28 (30.77)	29 (32.22)	0.833
Cholelithiasis	17 (18.68)	16 (17.78)	0.875
Previous pancreatitis, n (%)	9 (9.89)	10 (11.11)	0.789
APACHE-II score on admission (mean ± SEM)	12.6 ± 0.8	12.2 ± 0.8	0.724
Ranson score on admission (mean ± SEM)	3.3 ± 0.3	3.2 ± 0.4	0.842
Necrotizing pancreatitis	23 (25.27)	20 (22.22)	0.727
Time from the onset to diagnosis (hours)	15.2 ± 6.5	14.6 ± 7.1	0.950
Endoscopic bile duct drainage	37 (40.66)	42 (46.67)	0.455

UTI: Ulinastatin: BMI: Body mass index; APACHE: Acute Physiology and Chronic Health Evaluation.